These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9350483)

  • 1. Causes and consequences of hyperhomocyst(e)inemia.
    Pietrzik K; Brönstrup A
    Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperhomocyst(e)inemia--an independent risk factor of stroke].
    Lalouschek W; Aull S; Deecke L; Schnider P; Uhl F; Zeiler K
    Fortschr Neurol Psychiatr; 1996 Jul; 64(7):271-7. PubMed ID: 8765893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.
    Kang SS; Wong PW
    Atherosclerosis; 1996 Jan; 119(2):135-8. PubMed ID: 8808490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background.
    Moghadasian MH; McManus BM; Frohlich JJ
    Arch Intern Med; 1997 Nov; 157(20):2299-308. PubMed ID: 9361570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
    Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
    Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
    Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
    Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocyst(e)inemia--determining factors and treatment.
    Genest J
    Can J Cardiol; 1999 Apr; 15 Suppl B():35B-38B. PubMed ID: 10350684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension?
    Virdis A; Ghiadoni L; Salvetti G; Versari D; Taddei S; Salvett A
    J Nephrol; 2002; 15(4):414-21. PubMed ID: 12243373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
    Lentz SR; Malinow MR; Piegors DJ; Bhopatkar-Teredesai M; Faraci FM; Heistad DD
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2930-4. PubMed ID: 9409278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocyst(e)ine, vitamins and genetic interactions in vascular disease.
    Malinow MR
    Can J Cardiol; 1999 Apr; 15 Suppl B():31B-34B. PubMed ID: 10350683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.
    Henning BF; Zidek W; Riezler R; Graefe U; Tepel M
    Res Exp Med (Berl); 2001 Mar; 200(3):155-68. PubMed ID: 11426667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
    Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
    Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
    Stühlinger MC; Stanger O
    Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocyst(e)inemia in chronic stable renal transplant patients.
    Machado DJ; Paula FJ; Sabbaga E; Ianhez LE
    Rev Hosp Clin Fac Med Sao Paulo; 2000; 55(5):161-8. PubMed ID: 11175576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.
    Langman LJ; Ray JG; Evrovski J; Yeo E; Cole DE
    Arch Intern Med; 2000 Apr; 160(7):961-4. PubMed ID: 10761961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
    Falcon CR; Cattaneo M; Panzeri D; Martinelli I; Mannucci PM
    Arterioscler Thromb; 1994 Jul; 14(7):1080-3. PubMed ID: 8018663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives.
    Beaumont V; Malinow MR; Sexton G; Wilson D; Lemort N; Upson B; Beaumont JL
    Atherosclerosis; 1992 Jun; 94(2-3):147-52. PubMed ID: 1632868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia.
    Yoo JH; Choi GD; Kang SS
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1921-5. PubMed ID: 10938012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperhomocyst(e)inemia: physiological basis.
    Kang SS
    J Nutr; 1996 Apr; 126(4 Suppl):1273S-5S. PubMed ID: 8642469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.